At a Glance
- Company: LGM Pharma
- Location: Rosenberg, Texas; Aurora, Colorado
- Investment: $15M total ($6M Phase 1 2025; $9M Phase 2 2026)
- Focus area: Liquids, suspensions, semi-solids, suppositories
- Next steps: Increased prescription drug production
What happened?
LGM Pharma announced a $9 million second-phase investment in its US manufacturing facilities on 19 March 2026, bringing total recent expansion spend to $15 million across sites in Texas and Colorado. The upgrades target higher capacity for suppository, semi-solid, liquid and suspension drug products while maintaining full operations.
Why does it matter?
Expansions address rising demand for reliable US-based CDMO services amid supply chain risks and regulatory preferences for domestic production. LGM now supports more 505(b)(2) and ANDA projects, enhancing API sourcing, analytical testing and full lifecycle services for pharma clients.
Who’s behind it?
LGM Pharma is a full-service CDMO offering API procurement, formulation, manufacturing and testing. Backed by New Harbor Capital recapitalisation, it operates cGMP sites focused on prescription generics and branded products, with strong regulatory track records.
How was it achieved?
Phase 1 ($6M in 2025) upgraded Rosenberg, Texas for initial capacity; Phase 2 adds equipment, quality systems and serialisation at both sites. Enhancements ensure FDA/cGMP compliance for increased volumes of complex dosage forms like suppositories.
What’s next?
Facilities ramp up prescription production, including submitted ANDAs; LGM eyes further growth in niche markets like suppositories (projected $1.3B by 2035). Clients can engage via LGMPharma.com or events like DCAT Week.